Please assess the completion status of the following clinical trial:

Trial Title: Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and Female patients age 18 years or older~* COVID-19 confirmed positive test results~* High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score~* Hematology criteria: ANC \>500 cells/mcl, HGB \>9 g/dl, Platelet count \>75,000/mcl~* Metabolic criteria: Serum creatinine \<2.0 mg/dl or calculated creatinine clearance (using Cockcroft-Gault) \>30 ml/min, AST/ALT \<5x ULN AND Total Bilirubin WNL (for patients with Gilbert's disease, direct bilirubin \<ULN)~Exclusion Criteria:~* COVID-19 negative test result~* Inability to adhere to study protocol requirements~* Inability to provide informed consent~* Other acute or chronic medical or psychiatric condition that in the judgment of the investigator would make the participant inappropriate to take part in the study~* Pregnant and breastfeeding individuals~* QTc interval greater than 470 msecs at baseline~* History of hypersensitivity to atovaquone and/or azithromycin.~* History of known intolerance to atovaquone and/or azithromycin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Atovaquone/Azithromycin (Type: EXPERIMENTAL): Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)

Based on this trial design, predict the completion outcome and termination type (if applicable).